Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MoonLake Immunotherapeutics filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing sonelokimab (SLK) for inflammatory diseases. Form 8-K reports cover operating and financial results, clinical-trial disclosures for SLK programs, FDA meeting updates, Regulation FD communications, material agreements and capital-structure matters involving Class A ordinary shares.
Proxy materials describe annual meeting voting matters, including director elections, auditor ratification, executive compensation and amendments to the 2022 Equity Incentive Plan. The filing record also includes exhibits and registration-related disclosures tied to financings, governance matters and shareholder approvals.
MoonLake Immunotherapeutics is offering securities under a preliminary prospectus supplement for an aggregate offering amount of $150,000,000. The offering covers Class A Ordinary Shares and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.0001 per share. The underwriters have a 30‑day option to purchase up to $22,500,000 of additional Class A Ordinary Shares. The prospectus cites 72,134,066 Class A Ordinary Shares outstanding as of March 31, 2026 and discloses a last reported Nasdaq sale price of $22.16 on June 22, 2026. Net proceeds are intended to fund continued development and (if approved) commercialization of SLK (Sonelokimab) and for general corporate purposes. The prospectus supplement notes clinical Phase 3 VELA program results for SLK in hidradenitis suppurativa and discusses risks, dilution, PFIC tax considerations and limits on pre-funded warrant exercisability.
MoonLake Immunotherapeutics received an updated ownership report from a group of BVF-related investment funds and Mark N. Lampert, who together form a Section 13(d) group holding more than 10% of the company’s common stock. The filing mainly records existing Class A Ordinary Share positions and a new stock option award linked to director Spike Loy’s service. The option covers 22,195 Class A Ordinary Shares at an exercise price of $19.19 per share, expiring on June 17, 2036, and vests in full on the earlier of June 17, 2027 or the next annual general meeting of shareholders, subject to his continued service. The group and Mr. Loy each disclaim beneficial ownership beyond their economic interests.
MoonLake Immunotherapeutics reported final Week 52 Phase 3 VELA data for its Nanobody sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa, plus interim Phase 3 VELA-TEEN results in adolescents. Across VELA-1 and VELA-2, 67.2% of adults on SLK achieved HiSCR75 and 33.1% reached HiSCR100 at Week 52 (n=396), with 26.0% achieving IHS4-100 inflammatory remission. Patient-reported outcomes improved meaningfully, including large HiSQOL and DLQI gains and pain reduction in 46.5% of eligible adults. In VELA-TEEN, approximately 68% of adolescents achieved HiSCR75 and ~45% achieved HiSCR100 at Week 24 (n=22), with no new safety signals. MoonLake plans to submit a BLA for HS at the end of September 2026 and expects BLA acceptance and PDUFA date notification by the end of November 2026, with Priority Review viewed as an upside case.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of 17,876 Class A ordinary shares. The shares were sold on two days at weighted average prices of about $19.60 and $19.68 per share under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following these transactions, he continues to hold 1,154,555 shares directly.
MoonLake Immunotherapeutics director Andrew John Phillips received a grant of stock options covering 22,195 shares. These options have an exercise price of $19.19 per share and relate to Class A ordinary shares.
The options vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, as long as he continues serving the company. After this grant, the filing shows 22,195 options held directly.
MoonLake Immunotherapeutics director Loy Spike received a compensation-related stock option grant. The award covers 22,195 options to buy Class A ordinary shares at an exercise price of $19.19 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 17, 2027 or the company’s next annual general meeting of shareholders, as long as Spike continues to serve the company. The option expires on June 17, 2036 if not exercised.
MoonLake Immunotherapeutics director Catherine Moukheibir received a grant of options to buy 22,195 Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036. All 22,195 options are shown as held directly after the transaction.
According to the terms, the options will vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, as long as she continues to serve the company.
MoonLake Immunotherapeutics director Xavier Ramnik received a grant of stock options covering 22,195 Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036.
The option grant vests in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, subject to Ramnik’s continued service. After this grant, he holds options for 22,195 shares.
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported open-market sales of a total of 150,000 Class A ordinary shares associated with him over three days. The shares are owned by JeruCON Beratungsgesellschaft mbH, where he is deemed an indirect beneficial owner.
The indirect holdings sold were 50,000 shares on each of June 15, 16, and 17, 2026, at weighted average prices of about $18.89, $18.70, and $19.43 per share, within price ranges from roughly $18.24 to $19.97. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 10, 2026.
After these sales, JeruCON’s indirect position is reported as 2,824,551 shares, while Reich also holds 35,389 shares directly, indicating that he retains a substantial equity interest in MoonLake Immunotherapeutics following the transactions.